Rewarding innovation in vaccine research

A nearly $200,000 grant from the Rhode Island Science and Technology Advisory Council allows researchers, including EpiVax Inc. founder Annie De Groot, above, to continue work on an anti-tick vaccine delivered through the use of a transdermal patch. De Groot has been working with University of Rhode Island researchers on the vaccine, which remains years away from the marketplace. The grant allows Isis Biopolymer Inc. to join in the project, to help develop a delivery system for the vaccine. /
A nearly $200,000 grant from the Rhode Island Science and Technology Advisory Council allows researchers, including EpiVax Inc. founder Annie De Groot, above, to continue work on an anti-tick vaccine delivered through the use of a transdermal patch. De Groot has been working with University of Rhode Island researchers on the vaccine, which remains years away from the marketplace. The grant allows Isis Biopolymer Inc. to join in the project, to help develop a delivery system for the vaccine. /

A nearly $200,000 grant from the Rhode Island Science and Technology Advisory Council allows researchers, including EpiVax Inc. founder Annie De Groot, above, to continue work on an anti-tick vaccine delivered through the use of a transdermal patch. De Groot has been working with University of Rhode Island researchers on the vaccine, which remains years away from the marketplace. The grant allows Isis Biopolymer Inc. to join in the project, to help develop a delivery system for the vaccine.

No posts to display